Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Biological Buffers Market size was over USD 846.2 billion in 2024 and is expected to reach USD 2.03 trillion by the end of 2037, registering at a CAGR of 7.6% during the forecast timeline, i.e., 2025-2037. In 2025, the industry size of biological buffers is assessed at USD 910.5 billion.
The market constitutes the invention and supply of chemical compounds crucial for preserving pH steadiness in countless biological and biochemical procedures. These buffers are vivacious for abundant laboratory submissions that include molecular biology, cell culture, and protein biochemistry, thereby driving the demand throughout the life sciences sector. According to the February 2023 article published by Science Repository Organization, bicarbonate buffers in the blood comprise a pH level of 7.40 mostly composed of carbonic acid and its conjugate base, bicarbonate. This ensures stabilization in biological systems, thus amplifying the market growth internationally.
Furthermore, biological buffers are vital in pharmaceutical products to uphold optimum pH, guaranteeing drug firmness, solubility, efficiency, and protection, as well as imitating physiological circumstances for management. Therefore, the export and import of such products eventually drive the demand for the biological buffers market globally. Based on this, the 2023 OEC report denoted the world trade valuation of pharmaceutical products is USD 854 billion and is positioned at 6th as the most traded product. Additionally, its top exporter is Germany at a worth of USD 115 billion, and the top importer is the United States with USD 170 billion.
Country-wise Pharmaceutical Products Export/Import
|
Countries |
Export |
Import |
|
Germany |
USD 115 billion |
USD 71.1 billion |
|
United States |
USD 100 billion |
USD 170 billion |
|
Ireland |
USD 92 billion |
- |
|
Switzerland |
USD 80.7 billion |
USD 58.2 billion |
|
Belgium |
USD 52.1 billion |
USD 54.1 billion |
|
China |
- |
USD 45.4 billion |
Source: OEC 2023
Biological Buffers Sector: Growth Drivers and Challenges
Growth Drivers
- Expansion of the biopharmaceutical sector: The steady growth and expansion of the industry is a driving factor for the upliftment of the biological buffers market internationally. Biopharmaceutical organizations through agreements are evolving biologic drugs, swelling the demand for high-quality buffers crucial for sustaining optimum pH levels during drug creation, distillation, and invention processes. For instance, in September 2022, Spectrum Chemical Mfg. Corp signed the U.S. distribution deal with DFE Pharma to provide BioHale Brand products for biopharmaceutical manufacturing, thus driving market evolution.
- Increasing demand for customized medicines: The sudden shift towards precision medicine is knowingly driving the necessity for sophisticated biological buffers, which in turn is amplifying the biological buffers market. According to a report by Research Nester, the global precision medicine market is expected to expand at a growth rate of 16.7% by 2037 with an effective focus on the drug development pipeline. Besides, this category of medicine comprises novel therapy solutions based on separate genetic profiles, which need buffers that can preserve the steadiness and effectiveness of these highly precise biologics.
Challenges
- Presence of strict regulations: The biological buffers market faces considerable negative encounters based on the presence of stringent regulatory policies. This is because the research and manufacturing of pharmaceutical products require severe quality control ethics and certification set by supervisory bodies such as the FDA and EMA. This compliance structure, however, upsurges production costs and time-to-market. Besides, organizations also ensure investment to meet these standards, which in turn reduces the unveiling of the latest products and services in the market.
- High cost and price sensitivity: The aspect of cost-effective solutions is actively adopted by small-scale biotech companies and academic research institutions that account for limited budget allocation. This price sensitivity mitigates producers to maintain an equilibrium between upholding high product excellence and offering modest pricing, which hinders the expansion of the biological buffers market globally. In addition, a few research labs cater to in-house buffer research to cut costs, thereby dipping the demand for commercial buffer products.
Biological Buffers Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
7.6% |
|
Base Year Market Size (2024) |
USD 846.2 billion |
|
Forecast Year Market Size (2037) |
USD 2.03 trillion |
|
Regional Scope |
|
Biological Buffers Segmentation
Form (Liquid Buffers, Powder Buffers)
By 2037, liquid buffers biological buffers market is likely to account for around 72.1% share. The aspect of continuous advancements in liquid-based handling technologies is the driving factor responsible for the segment’s growth. According to the October 2024 AIJMR report, the international market size for automated liquid handling was USD 1,181.8 million in 2022 and by 2032 the market is assessed to reach approximately USD 2,580.4 million. Therefore, this growth is subjected to aid researchers in developing drugs, genomics, and molecular biology as well as enhance accuracy and diminish cost, time, and error, thus driving the segment’s growth.
Application (Research Laboratories, Clinical Laboratories, Pharmaceutical Industry, Biotechnology Industry, Academic Institutes)
In biological buffers market, research laboratories segment is set to hold revenue share of more than 42.9% by 2037. This segment plays an essential role in both analytical and experimental procedures, including the precision essential for maintaining consistency and quality of critical biological buffers. As per the April 2024 Phys Organization report, the phase separation of the SARS-CoV-2 N protein sturdily depends on the selected buffer and pH. Moreover, with the use of phosphate buffer in laboratories, researchers can produce phase separation for non-physiological pH 6, thus thriving the segment’s growth.
Our in-depth analysis of the global biological buffers market includes the following segments:
|
Form |
|
|
Type |
|
|
Application |
|
|
End User |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportBiological Buffers Industry - Regional Synopsis
Europe Market Analysis
Europe biological buffers market is expected to capture revenue share of over 41.6% by 2037. The region is subjected to substantial investments, especially in the pharmaceutical industry. This eventually resulted in the advancement of revolutionary biological buffer infrastructures and technologies that have the capability to produce high-quality buffers. In addition, there is ample support from the regional Union regarding scientific research and development at both regional and international levels through numerous organizations and agencies that deliver capital for biological buffer research.
The biological buffers market in the U.K. is gaining more traction due to the provision of investment initiated by government and administrative bodies. For instance, as per the January 2025 UK Bioindustry Association report, the regional biotech industry experienced significant growth in 2024. This was possible with the provision of an investment of £3.5 billion (USD 4.5 billion), which is a staggering increase of 94% in comparison to the previous year. Therefore, with such investment, it is expected that the country will experience innovation in biotechnology that will eventually support the manufacturing and production of biological buffers, thereby driving market upliftment.
The biological buffers market in Germany is anticipated to increase owing to effective contributions initiated by companies. For instance, in October 2024, Rentschler Biopharma SE declared the creation of a novel and advanced buffer media station at its company headquarters in Laupheim. The latest developed facility aimed to additionally surge the production effectiveness and revolutionize the site. This further ensured that the developing requirements of clients and patients are estimated and fully met, both at the present and in the future, thus denoting a prolific upgrade of the market in the country.
APAC Market Statistics
The biological buffers market in the Asia Pacific is predicted to determine the fastest growth during the forecast timeline. Factors such as increased investments in research and development activities pertaining to life sciences, enhancement of biopharmaceuticals and diagnostics, and partnerships between pharmaceutical organizations are readily driving the market in the region. Besides, in March 2023, Novotech published multi-specific monoclonal antibodies clinical trial reports that included more than 1,000 clinical trials with the Asia Pacific region accounting for 40% of these trials, thus bolstering market evolution in the region.
The biological buffers market in India has achieved more exposure owing to the presence of regional manufacturers highly responsible for the production of different types of buffers. For instance, CDH Fine Chemical is the foremost biological buffers for Cell Culture Tested Chemical products manufacturers, suppliers, and exporters from the country. In one of its 2025 reports, the organization enlisted the manufacturing of different types of buffers. These included BES buffer, BIS TRIS, Glycyl Glycine 99.0%, MES Sodium Salt 99.0%, MOPS Sodium Salt 98.0%, Tris Base, Tris Hydrochloride, and others, positively impacting market expansion.
There is a significant presence of the biological buffers market in China based on regional companies, highly responsible for the production of different types of buffers. For instance, in October 2022, ANGUS Chemical Company declared the marketable launch of HEPES buffer produced at its Sterlington, Louisiana facility. HEPES is a multi-purpose biological buffer frequently utilized to uphold a physiological pH that delivers the perfect environment for cells to cultivate and flourish. This development of the global organization expanded its portfolio in the country and positioned itself as the hub of HEBES molecule production.
Companies Dominating the Biological Buffers Landscape
- Avantor, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Merck KGaA
- Thermo Fisher Scientific Inc.
- Lonza Group AG
- Bio-Rad Laboratories, Inc.
- GE Healthcare
- Corning Incorporated
- Promega Corporation
- MP Biomedicals, LLC
- Becton, Dickinson and Company
- QIAGEN N.V.
- Repligen Corporation
- Roche Diagnostics
- Biological Industries
- GeminiBio
- Aceto
In the biological buffers market, key companies meaningfully inspire industrial standards and innovation through effective partnerships, collaborations, and mergers and acquisitions. For instance, in July 2024, GSK plc and Flagship Pioneering notified their collaboration to discover and develop a portfolio of future transformational medicines and vaccines, with a preliminary focus on respiratory and immunology. This association brought together GSK’s disease area expertise and growth competence with Flagship’s network of bioplatform companies, all-encompassing of its innovative modalities and technologies, to make developments in healthcare.
Here's the list of some key players:
In the News
- In March 2025, GeminiBio and Asahi Kasei Bioprocess America entered into a strategic partnership to advance the application of inline buffer formulation (IBF) in the biopharmaceutical industry.
- In October 2021, Aceto stated its acquisition of A&C Bio Buffer Ltd, a GMP manufacturer of custom buffer and chemical blend products utilized in the manufacturing of biopharmaceutical drug products. This complemented Aceto’s acquisition and reinforced the company’s prolonged business development efforts in the biopharmaceutical sector.
Author Credits: Radhika Pawar
- Report ID: 7404
- Published Date: Mar 27, 2025
- Report Format: PDF, PPT
